Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

I am a Healthcare Professional in the HKSARYes, I am a healthcare professional
SelectI am a Healthcare Professional in the HKSARYes, I am a healthcare professional
I am NOT a Healthcare ProfessionalNo, go back to the patient portal
SelectI am NOT a Healthcare ProfessionalNo, go back to the patient portal

I am a healthcare professional in another country

CONGRESS MATERIALS

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Poster
Russell-Smith A, Shah R, Silverstein AR, Petrilla A, Leinwand B, Norris D, Schroeder A June 10, 2022 EHA 2022 Hematology

Characteristics, Healthcare Utilization, and Costs Associated With Inotuzumab Ozogamicin, Blinatumomab, or Other Agents for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

View Presentation
Poster
Gambacorti-Passerini C, Brummendorf TH, Ernst T, Leip E, Purcell S, Viqueira A, Giles FJ, Rosti G, Hochhaus A June 10, 2022 EHA 2022 Hematology

Efficacy and Safety of Bosutinib in Later-Line Patients With Chronic Myeloid Leukemia: A Sub-Analysis From the Phase 4 BYOND Trial

View Presentation View Abstract Plain Language Summary
Poster
Dalovisio A, Bahlis NJ, Raje NS, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Sebag M, Lesokhin AM June 10, 2022 EHA 2022 Hematology

Updated Results From the Ongoing Phase 1 Study of Elranatamab, a BCMA Targeted T-Cell Redirecting Immunotherapy, for Patients With Relapsed or Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Deininger MW, Brummendorf TH, Lipton JH, Milojkovic D, Stenke L, Leip E, Purcell S, Viqueira A, Cortes JE December 10, 2022 ASH 2022 Hematology

Efficacy and Safety of Bosutinib Versus Imatinib by Charlson Comorbidity Index in Newly Diagnosed Patients With Chronic Myeloid Leukemia

View Presentation View Abstract Plain Language Summary
Oral Presentation
Bahlis N, Tomasson MH, Mohty M, Niesvizky R, Nooka A, Manier S, Maisel C, Jethava Y, Martinez-Lopez J, Prince HM, Arnulf B, Rodriguez-Otero P, Koehne G, Touzeau C, Raje N, Iida S, Raab M-S, Leip E, Sullivan S, Conte U, Viqueira A, Lesokhin A December 10, 2022 ASH 2022 Hematology

Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma Naïve to B-cell Maturation Antigen (BCMA)-Directed Therapies: Results From Cohort A of the MagnetisMM-3 Study

View Presentation View Abstract Plain Language Summary
Poster
Grosicki S, Mellqvist U-H, Pruchniewski L, Crafoord J, Trudel S, Min C-K, White D, Alegre A, Hansson M, Ikeda T, Sunami K, Leip E, Kudla A, Finn G, Koh Y December 10, 2022 ASH 2022 Hematology

Elranatamab in Combination With Daratumumab for Patients With Relapsed/Refractory Multiple Myeloma: Results From the Phase 3 MagnetisMM-5 Study Safety Lead-In Cohort

View Presentation View Abstract Plain Language Summary
Oral Presentation
Raje NS, Bahlis NJ, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Dalovisio A, Sebag M, Lesokhin AM December 10, 2022 ASH 2022 Hematology

Elranatamab, a BCMA-Targeted T-cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients With Relapsed or Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Gajra A, Kish JK, Russell-Smith A, Savill KMZ December 10, 2022 ASH 2022 Hematology

Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated With Glasdegib or Venetoclax in US Community Oncology Practices

View Presentation View Abstract Plain Language Summary
Poster
Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Hibma J, Lon H-K, Piscitelli J, Soltantabar P, Wang D, Jiang S, Finn G, Czibere A December 11, 2022 ASH 2022 Hematology

Dose Optimization to Mitigate the Risk of CRS With Elranatamab in Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Kota V, Deininger MW, Mendler JH, Shen W, Goldman EH, Cortes JE December 11, 2022 ASH 2022 Hematology

Efficacy and Safety of Bosutinib Versus Imatinib in US Patients With Newly Diagnosed Chronic Myeloid Leukemia After 5-Years Follow-Up in the BFORE Trial

View Presentation View Abstract Plain Language Summary